Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW.

Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31050-9. doi: 10.1016/j.eururo.2018.12.042. [Epub ahead of print]

PMID:
30638634
2.

Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.

Sabouri S, Chang SD, Goldenberg SL, Savdie R, Jones EC, Black PC, Fazli L, Kozlowski P.

NMR Biomed. 2019 Feb;32(2):e4048. doi: 10.1002/nbm.4048. Epub 2018 Dec 21.

PMID:
30575145
3.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.

Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BWG, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JWF, Xylinas E, Hendricksen K; Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology.

Eur Urol Focus. 2018 Dec 14. pii: S2405-4569(18)30382-1. doi: 10.1016/j.euf.2018.12.002. [Epub ahead of print]

PMID:
30559065
4.

Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.

da Costa JB, Gibb EA, Nykopp TK, Mannas M, Wyatt AW, Black PC.

Urol Oncol. 2018 Dec 8. pii: S1078-1439(18)30463-0. doi: 10.1016/j.urolonc.2018.11.015. [Epub ahead of print] Review.

PMID:
30528886
5.

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer.

Ingersoll MA, Li X, Inman BA, Greiner JW, Black PC, Adam RM.

Bladder Cancer. 2018 Oct 29;4(4):429-440. doi: 10.3233/BLC-180175.

6.

Current Clinical Trials in Non-muscle Invasive Bladder Cancer.

Nykopp TK, Batista da Costa J, Mannas M, Black PC.

Curr Urol Rep. 2018 Oct 24;19(12):101. doi: 10.1007/s11934-018-0852-6. Review.

PMID:
30357541
7.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

PMID:
30345422
8.

Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.

Oo HZ, Seiler R, Black PC, Daugaard M.

Urol Oncol. 2018 Oct 17. pii: S1078-1439(18)30339-9. doi: 10.1016/j.urolonc.2018.09.001. [Epub ahead of print] Review.

PMID:
30342880
9.

Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts.

Nir G, Hor S, Karimi D, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Wilson RS, Iczkowski KA, Lucia MS, Black PC, Abolmaesumi P, Goldenberg SL, Salcudean SE.

Med Image Anal. 2018 Dec;50:167-180. doi: 10.1016/j.media.2018.09.005. Epub 2018 Sep 24.

PMID:
30340027
10.

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF.

Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26. Review.

PMID:
30268659
11.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

PMID:
30262589
12.

Immune system trickery and deception: Allograft-derived neuroendocrine carcinoma post kidney transplantation.

Chehroudi C, Mannas M, Jones EC, Nguan C, Oja C, Black PC.

Urol Case Rep. 2018 Sep 14;21:89-91. doi: 10.1016/j.eucr.2018.09.007. eCollection 2018 Nov. No abstract available.

13.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
14.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB.

Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3. Review.

PMID:
30190111
15.

A risk-stratified approach to the management of high-grade T1 bladder cancer.

Mannas MP, Lee T, Nykopp TK, Costa JBD, Black PC.

Curr Opin Urol. 2018 Nov;28(6):563-569. doi: 10.1097/MOU.0000000000000548.

PMID:
30148753
16.

Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Ghavimi S, Abdi H, Waterhouse J, Savdie R, Chang S, Harris A, Machan L, Gleave M, So AI, Goldenberg L, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):270-275. doi: 10.4859/cuaj.4859. Epub 2018 Apr 6.

17.

New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Bladder Cancer. 2018 Jul 30;4(3):339-342. doi: 10.3233/BLC-189032. No abstract available.

18.

Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.

Kesch C, Black PC.

Urology. 2018 Nov;121:1-2. doi: 10.1016/j.urology.2018.07.007. Epub 2018 Aug 2. No abstract available.

PMID:
30077538
19.

The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer.

Lichtenegger E, Koll F, Haas H, Mantwill K, Janssen KP, Laschinger M, Gschwend J, Steiger K, Black PC, Moskalev I, Nawroth R, Holm PS.

Hum Gene Ther. 2019 Jan;30(1):44-56. doi: 10.1089/hum.2018.026. Epub 2018 Aug 3.

PMID:
29916265
20.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2018 Jun 7. doi: 10.1007/s00345-018-2361-0. [Epub ahead of print]

PMID:
29882105
21.

Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection.

Park ES, Yan JP, Ang RA, Lee JH, Deng X, Duffy SP, Beja K, Annala M, Black PC, Chi KN, Wyatt AW, Ma H.

Lab Chip. 2018 Jun 12;18(12):1736-1749. doi: 10.1039/c8lc00184g.

PMID:
29762619
22.

Magnet Before the Needle Commentary on: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis (PRECISION Trial).

Merrett C, Mannas M, Black PC, Zargar H.

Urology. 2018 Aug;118:1-2. doi: 10.1016/j.urology.2018.04.024. Epub 2018 May 3. No abstract available.

PMID:
29730255
23.

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.

24.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

PMID:
29672836
25.

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM.

Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12.

26.

Unravelling disparate roles of NOTCH in bladder cancer.

Goriki A, Seiler R, Wyatt AW, Contreras-Sanz A, Bhat A, Matsubara A, Hayashi T, Black PC.

Nat Rev Urol. 2018 Jun;15(6):345-357. doi: 10.1038/s41585-018-0005-1. Review.

PMID:
29643502
27.

Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Ghavimi S, Abdi H, Waterhouse J, Savdie R, Chang S, Harris A, Machan L, Gleave M, So A, Goldenberg L, Black PC.

Can Urol Assoc J. 2018 Apr 6. doi: 10.5489/cuaj.4859. [Epub ahead of print]

PMID:
29629864
28.

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Chung P, Drachenberg D, Fradet Y, Jacobsen N, Morash C, Shayegan B, Gotto G, Zlotta A, Fleshner N, Siemens DR, Black PC.

Can Urol Assoc J. 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19. No abstract available.

29.

Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Kesch C, Black PC.

Urology. 2018 Jun;116:1-2. doi: 10.1016/j.urology.2018.03.007. Epub 2018 Mar 27. No abstract available.

PMID:
29596865
30.

Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Urol Oncol. 2018 Sep;36(9):403-404. doi: 10.1016/j.urolonc.2017.11.006. Epub 2018 Mar 13. No abstract available.

PMID:
29548621
31.

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.

Todenhöfer T, Struss WJ, Seiler R, Wyatt AW, Black PC.

Bladder Cancer. 2018 Jan 20;4(1):19-29. doi: 10.3233/BLC-170140. Review.

32.

Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary.

Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, Nicolai N, Nichols C.

Eur Urol. 2018 Jun;73(6):899-907. doi: 10.1016/j.eururo.2017.12.030. Epub 2018 Jan 12. Review.

PMID:
29338978
33.

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.

Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W; Collaborators.

J Urol. 2018 Jun;199(6):1452-1458. doi: 10.1016/j.juro.2017.12.062. Epub 2018 Jan 9.

PMID:
29329894
34.

Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.

Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S.

CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.

35.

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG.

Urol Oncol. 2018 Sep;36(9):413-422. doi: 10.1016/j.urolonc.2017.10.014. Epub 2017 Nov 8. Review.

PMID:
29128420
36.

Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.

Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC.

J Urol. 2018 May;199(5):1129-1142. doi: 10.1016/j.juro.2017.10.041. Epub 2017 Nov 4. Review. Erratum in: J Urol. 2018 Sep;200(3):660.

PMID:
29113841
37.

Perspectives on the discovery of NOTCH2-specific inhibitors.

Dobranowski P, Ban F, Contreras-Sanz A, Cherkasov A, Black PC.

Chem Biol Drug Des. 2018 Mar;91(3):691-706. doi: 10.1111/cbdd.13132. Epub 2017 Nov 15.

PMID:
29078041
38.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA.

Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18. Review.

PMID:
29055653
39.

Orthotopic Mouse Models of Urothelial Cancer.

Jäger W, Moskalev I, Raven P, Goriki A, Bidnur S, Black PC.

Methods Mol Biol. 2018;1655:177-197. doi: 10.1007/978-1-4939-7234-0_15.

PMID:
28889387
40.

Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.

41.

Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.

Struss WJ, Black PC.

Urology. 2017 Nov;109:1-2. doi: 10.1016/j.urology.2017.07.032. Epub 2017 Aug 7. No abstract available.

PMID:
28797683
42.

Evolving attitudes toward robotic surgery among Canadian urology residents.

Locke J, Robinson M, MacNeily A, Goldenberg SL, Black PC.

Can Urol Assoc J. 2017 Jul;11(7):E266-E270. doi: 10.5489/cuaj.4222. Epub 2017 Jul 11.

43.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31.

44.

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2017 Jul 24;8(1):103. doi: 10.1038/s41467-017-00147-w.

45.

Identifying intermediate-risk candidates for active surveillance of prostate cancer.

Savdie R, Aning J, So AI, Black PC, Gleave ME, Goldenberg SL.

Urol Oncol. 2017 Oct;35(10):605.e1-605.e8. doi: 10.1016/j.urolonc.2017.06.048. Epub 2017 Jul 20. Review.

PMID:
28736249
46.

Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.

Kobatake K, Hayashi T, Black PC, Goto K, Sentani K, Kaneko M, Yasui W, Mita K, Teishima J, Matsubara A.

Int J Urol. 2017 Aug;24(8):594-600. doi: 10.1111/iju.13389. Epub 2017 Jul 22.

47.

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.

48.

Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.

Klaassen Z, Li K, Kassouf W, Black PC, Dragomir A, Kulkarni GS.

Can Urol Assoc J. 2017 Jun;11(6):173-181. doi: 10.5489/cuaj.4568.

50.

Dose dense MVAC prior to radical cystectomy: a real-world experience.

Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshmand S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W.

World J Urol. 2017 Nov;35(11):1729-1736. doi: 10.1007/s00345-017-2065-x. Epub 2017 Jun 17.

PMID:
28625005

Supplemental Content

Loading ...
Support Center